Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer

Urology

Volumn 61, Issue 3, 2003, Pages 539-543

  Gilbert, Scott M ^b   Veltri, Robert W ^b   Sawczuk, Alex ^b   Shabsigh, Ahmad ^b   Knowles, David R ^b   Bright, Steven ^b   O'Dowd, Gerald J ^b   Olsson, Carl A ^b   Benson, Mitchell C ^b   Sawczuk, Ihor S ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TUMOR BIOPSY; URINE CYTOLOGY;

EID: 0346035816     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02400-7     Document Type: Article

References (14)

1. Greenlee R.T., Murray T., Hill-Harmon M.B., et al. Cancer statistics, 2000. CA Cancer J Clin. 50:2000;7-33.
2. Messing E.M., Young T.B., Hunt V.B., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 45:1995;387-396.
3. Herr H.W. Natural history of superficial bladder tumors 10- to 20-year follow-up of treated patients . World J Urol. 15:1997;84-88.
4. Prout G.R. Jr, Barton B.A., Griffin P.P., et al. Treated history of noninvasive grade I transitional cell carcinomas. J Urol. 148:1992;1413-1419.
5. Cajulis R.S., Haines G.K. III, Frias-Hidvegi D., et al. Cytology, flow cytometry, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes a comparative study . Diagn Cytopathol. 13:1995;214-223.
6. Konety B.R., Getzenberg R.H. Urine based markers of urological malignancy. J Urol. 165:2001;600-611.
7. Lokeshwar U.B., Soloway M.S. Current bladder tumor tests does their projected utility fulfill clinical necessity? J Urol. 165:2001;1067-1077.
8. Grossman H.B., Washington R.W., Carey T.E., et al. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem. 161:(suppl):1992;63-68.
9. Brown F.M. Urine cytology is it still the gold standard for screening . Urol Clin North Am. 27:2000;25-37.
10. Konety B.R., Getzenberg R.H. Urine based markers of urological malignancy. J Urol. 165:2001;600-611.
11. Grossman H.B., Washington R.W. Jr, Corey T.E., et al. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem Suppl. 16I:1992;63-68.
12. Bonner R.B., Liebert M., Hurst R.E., et al. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Cancer Epidemiol Biomarkers Prev. 5:1996;971-978.
13. Ponsky L.E., Sharma S., Pandrangi L., et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol. 166:2001;75-78.
14. Konety BR, and Getzenberg RH: Urine based markers of urological malignancy. J Urol 165: 600-611, 2001